Cargando…

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies

BACKGROUND: Bispecific T cell engagers represent the majority of bispecific antibodies (BsAbs) entering the clinic to treat metastatic cancer. The ability to apply these agents safely and efficaciously in the clinic, particularly for solid tumors, has been challenging. Many preclinical studies have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poussin, Mathilde, Sereno, Arlene, Wu, Xiufeng, Huang, Flora, Manro, Jason, Cao, Shanshan, Carpenito, Carmine, Glasebrook, Andrew, Powell Jr, Daniel J, Demarest, Stephen J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8276301/ https://www.ncbi.nlm.nih.gov/pubmed/34253637 http://dx.doi.org/10.1136/jitc-2021-002444

Ejemplares similares

Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer
por: Huan, Tian, et al.
Publicado: (2023)

Dichotomous and stable gamma delta T-cell number and function in healthy individuals
por: Ou, Lingling, et al.
Publicado: (2021)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

Correction: Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
Publicado: (2021)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
por: Dang, Kevin, et al.
Publicado: (2021)

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2021)

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021)

First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
por: Schaller, Teilo H, et al.
Publicado: (2020)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
por: Leclercq, Gabrielle, et al.
Publicado: (2022)

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022)

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Spatial multi-omics revealed the impact of tumor ecosystem heterogeneity on immunotherapy efficacy in patients with advanced non-small cell lung cancer treated with bispecific antibody
por: Song, Xinyu, et al.
Publicado: (2023)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation
por: Gao, Jing, et al.
Publicado: (2023)

Bispecific antibody CD73xEGFR more selectively inhibits the CD73/adenosine immune checkpoint on cancer cells and concurrently counteracts pro-oncogenic activities of CD73 and EGFR
por: Ploeg, Emily Maria, et al.
Publicado: (2023)

TEM8 Tri-specific Killer Engager binds both tumor and tumor stroma to specifically engage natural killer cell anti-tumor activity
por: Kaminski, Michael F, et al.
Publicado: (2022)

Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
por: Lum, Lawrence G., et al.
Publicado: (2021)

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
por: Fabian, Kellsye P, et al.
Publicado: (2020)

Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186
por: Dettling, Danielle E, et al.
Publicado: (2022)

Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers
por: Roche, Veronique, et al.
Publicado: (2023)

Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve
por: Fabian, Kellsye P, et al.
Publicado: (2021)

FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells
por: Campos Carrascosa, Lucia, et al.
Publicado: (2020)

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)
por: Postel-Vinay, Sophie, et al.
Publicado: (2023)

Generalizable design parameters for soluble T cell receptor-based T cell engagers
por: Froning, Karen J, et al.
Publicado: (2022)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
por: Mulkey, Flora, et al.
Publicado: (2020)

CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression
por: Meetze, Kristan, et al.
Publicado: (2023)

P059: Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
por: Shi, Zhiyuan, et al.
Publicado: (2022)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
por: Carbone, Carmine, et al.
Publicado: (2021)

Avelumab for advanced Merkel cell carcinoma in the Netherlands: a real-world cohort
por: Levy, Sonja, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_54o5ipvaj328fuvh3n0jo46lqc